Damora Therapeutics Posts FY25 Results, Advances MutCALR Blood-Disorder Pipeline

Damora Therapeutics reported full-year 2025 results and highlighted progress across its pipeline targeting mutant calreticulin (mutCALR)-driven blood disorders, including essential thrombocythemia and myelofibrosis. The update is constructive for the company's clinical-stage outlook but provided no financial details or new regulatory milestones, so expect limited near-term market impact absent trial readouts or guidance.

Analysis

Damora Therapeutics reported full-year 2025 results and highlighted progress across its pipeline targeting mutant calreticulin (mutCALR)-driven blood disorders, including essential thrombocythemia and myelofibrosis. The update is constructive for the company's clinical-stage outlook but provided no financial details or new regulatory milestones, so expect limited near-term market impact absent trial readouts or guidance.